COMMUNIQUÉ DE PRESSE
News
-
-
-
-
COMMUNIQUÉ DE PRESSE
BRAIN Biotech AG presents strong cash position with its 9M reporting and is forecasting good sequential growth in the final quarter of the business year
BRAIN Biotech AG reports strong cash position for 9M period, forecasting growth in Q4 FY 23/24. BioProducts segment turnover slightly up, BioScience segment facing decline -
-
-
COMMUNIQUÉ DE PRESSE
BRAIN Biotech AG announces the appointment of Erik de Vries as Senior Business Development Director Enzymes
BRAIN Biotech AG appoints Erik de Vries as Senior Business Development Director Enzymes. De Vries will transition from CEO of Enzymicals AG to BRAIN Biotech's Supervisory Board in 2025 -
-
-
COMMUNIQUÉ DE PRESSE
BRAIN Biotech AG receives major milestone payment and stays on-track to achieve year end targets
BRAIN Biotech AG receives significant milestone payment of € 1.5 million and maintains progress towards year-end goals with strengthened cash position. Half-year results show revenue growth and improved EBITDA
